Companion diagnostics

Companion diagnostics

Deliver Personalized Healthcare to those who need it

For every ten cancer patients treated, an average of only half will benefit. For some, the treatment won’t have any effect; others may suffer from serious side effects.1 Ventana Medical Systems, Inc. A Member of the Roche Group is working at our ­industry’s forefront to change this ­dynamic by customizing therapy to individual patients, helping you to improve diagnostic accuracy, lab efficiency and patient safety.

In collaboration with leading pharmaceutical companies, we identify and develop innovative companion diagnostics to target those patients who are likely to respond to specific therapies. Because we recognize the tremendous potential for these solutions, we continue to focus on addressing unmet medical needs by developing the cutting-edge tools you need.

You can be confident that VENTANA ­products, from Roche, are the right ­solution to empower you to deliver the high-quality diagnostic information for patients — today and in the future.

One of the global leaders in tissue-based cancer diagnostics, we provide a premier end-to-end offering, with expertise at every stage from discovery to commercialization. Working together under one roof, Roche and ­pharma increase the efficiency and speed of developing patient selection biomarkers.

  • Brings 180+ biomarker projects with a strong track record — reliably on time and on budget
  • Provides global access through the Roche commercial network and install base
  • Offers a differentiated, broad instrument and reagent portfolio


Helping to deliver the promise of Personalized Healthcare

  • Companion tissue tests help determine the best course of treatment
  • We are committed to expanding our market-leading HER2 diagnostic franchise
  • The VENTANA ALK IHC Rabbit Monoclonal Primary Antibody aids in early detection and treatment decisions for non-small cell lung cancer patients
  • The VENTANA PD-L1 assays generate ­results you can trust, so you can make timely diagnostic decisions and therapeutic choices
  • The majority of the Roche oncology-focused targeted therapies, currently in late stage clinical trials, have an associated VENTANA tissue companion diagnostic


Product portfolio:

  • HER2
  • HER2 Dual ISH
  • VENTANA PD-L1 (SP142)
  • VENTANA PD-L1 (SP263)


1 Source: Roche Personalized Healthcare brochure, 2011.


Ventana ALK (D5F3) Rabbit Monoclonal Antibody

VENTANA PD-L1 (SP142) Assay

VENTANA PD-L1(SP263) Assay